Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma

BACKGROUND: Immunotherapy with immune checkpoint inhibitor (ICI) is a promising treatment for unresectable hepatocellular carcinoma (HCC). However, whether ICIs would have the risk of hepatitis B virus (HBV) reactivation and the necessary of nucleos(t)ide analogs (NUCs) prophylaxis are still unclear...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Pei-Chang, Chao, Yee, Chen, Ming-Huang, Lan, Keng-Hsin, Lee, I-Cheng, Hou, Ming-Chih, Huang, Yi-Hsiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462159/
https://www.ncbi.nlm.nih.gov/pubmed/32863270
http://dx.doi.org/10.1136/jitc-2020-001072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462159/
https://www.ncbi.nlm.nih.gov/pubmed/32863270
http://dx.doi.org/10.1136/jitc-2020-001072

Ejemplares similares